Supporting precise development of novel drugs

Together with the functional and/or genomic characterization of the cancer cells, the DS results can be used in any of the following ways:

Service Scope: Hematologic cancer sample

Service Options

Results

Process

01.
Immunophenotyping & genotyping

01. Immunophenotyping & genotyping

• Flow cytometry
• PCR for antigen receptor rearrangements (PARR)
• Gene mutations or expressions
• Immunophenotyping + genotyping report including prognostic information

Immunophenotyping
Assay

02.
Ex vivo drug sensitivity test

02. Ex vivo drug sensitivity test

• Ex vivo sensitivity of the new drug compound(s) on patients’ live cancer cells
• AI-driven drug response prediction scores for conventional drugs
• Time-course efficacy and prognosis prediction for a gold standard combinatorial protocol

Immunophenotyping
Assay

Drug Sensitivity Assay

03.
Responder vs. Non-responder

03. Responder vs. Non-responder

• Refined inclusion criteria for clinical trials based on responding patients’:

• Immune subtypes (antigen expression profiles using 10+ antibodies)
• Ex vivo responses against the new drug compound(s) and various other drugs
• Naive/relapse and signalment information, etc.

Immunophenotyping
Assay

Drug Sensitivity Assay

Data Analysis (Population-based)

04.
Identification of synergistic combination

04. Identification of synergistic combination

• Live-cell based, ex vivo population study data investigate new drug combinations between the existing drugs and the new drug compound(s)
• Mechanism of action study
• New target(s) identification

Immunophenotyping
Assay

Drug Sensitivity Assay

Data Analysis (Population-based)

05.
Response predictions for individual patients

05. Response predictions for individual patients

• All the above services throughout a clinical study or trial
• Development of a companion diagnostic AI model that predicts clinical response and prognosis of the new drug compound for individual patients
• Adding the new drug(s) to the drug panel in ImpriMed’s commercial services

Immunophenotyping
Assay

Drug Sensitivity Assay

Model Development
& Data Analysis
(Personalized)

We can offer any of the above services for drug candidates targeting human acute myeloid leukemia, or non-Hodgkin lymphoma. Please contact us at imprimedkorea@imprimedicine.com for further details or inquiries.